Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 13:10:579327.
doi: 10.3389/fonc.2020.579327. eCollection 2020.

CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation

Affiliations

CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation

Yuen Yee Cheng et al. Front Oncol. .

Abstract

Background: The diagnosis of malignant pleural mesothelioma (MPM) can be difficult, in part due to the difficulty in distinguishing between MPM and reactive mesothelial hyperplasia (RMH). The tumor suppressor gene, CDKN2A, is frequently silenced by epigenetic mechanisms in many cancers; in the case of MPM it is mostly silenced via genomic deletion. Co-deletion of the CDKN2A and methylthioadenosine phosphorylase (MTAP) genes has been researched extensively and discovered to be a highly specific characteristic of MPM. Most studies have used FISH to detect the deletion of CDKN2A and IHC for MTAP as a surrogate for this. In this study, we aim to investigate and validate droplet digital PCR (ddPCR) as an emerging alternative and efficient testing method in diagnosing MPM, by particularly emphasizing on the loss of MTAP and CDKN2A.

Methods: This study included 75 formalin fixed paraffin embedded (FFPE) MPM tissue, and 12 normal pleural tissue and 10 RMH as control. Additionally, primary MPM cell lines and normal pleural samples were used as biomarker detection controls, as established in our previous publication. All FFPE specimens were processed to isolate the DNA, that was subsequently used for ddPCR detection of CDKN2A and MTAP. FFPE samples were also analyzed by fluorescence in situ hybridization (FISH) for CDKN2A and MTAP deletion, and for MTAP IHC expression. Concordance of IHC and ddPCR with FISH were studied in these samples.

Results: 95% and 82% of cases showed co-deletion of both MTAP and CDKN2A when determined by FISH and ddPCR respectively. ddPCR has a sensitivity of 72% and specificity of 100% in detecting CDKN2A homozygous loss in MPM. ddPCR also has a concordance rate of 92% with FISH in detecting homozygous loss of CDKN2A. MTAP IHC was 68% sensitive and 100% specific for detecting CDKN2A homozygous loss in MPM when these losses were determined by ddPCR.

Conclusion: Our study confirms that MTAP is often co-deleted with CDKN2A in MPM. Our in-house designed ddPCR assays for MTAP and CDKN2A are useful in differentiating MPM from RMH, and is highly concordant with FISH that is currently used in diagnosing MPM. ddPCR detection of these genetic losses can potentially be utilized as an alternative method in the diagnosis of MPM and for the future development of a less-invasive MPM-specific detection technique on MPM tumor tissue DNA.

Keywords: CDKN2A; droplet digital PCR; fluorescence in situ hybridization; malignant pleural mesothelioma; methylthioadenosine phosphorylase.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A representative image showing epithelioid malignant pleural mesothelioma (MPM) with methylthioadenosine phosphorylase (MTAP) immunohistochemistry staining. Retained MTAP cytoplasmic expression (left); partial loss of MTAP cytoplasmic staining (middle) and complete loss of MTAP cytoplasmic staining (right); all with internal control lymphocytes with retained cytoplasmic staining for comparison (with arrows).
Figure 2
Figure 2
(A) Tri-color [methylthioadenosine phosphorylase (MTAP) – aqua, CDKN2A – red, CEPT9 – green] probe fluorescence in situ hybridization (FISH) staining showing genomic loss of MTAP and CDKN2A in mesothelioma cells from an operated malignant pleural mesothelioma (MPM) (P/D) sample, (B) FISH staining showing positive signals from all three probes in the reactive mesothelial hyperplasia (RMH) sample, where the inset shows two pairs of retained red CKDN2A and aqua MTAP genes. (C) Correlation between CDKN2A FISH results and MTAP FISH results with line of linear regression in black (slope = 1.007, y-intercept = −3.049, R2 = 0.989).
Figure 3
Figure 3
(A–D) Representative images of methylthioadenosine phosphorylase (MTAP) and CDKN2A droplet digital PCR (ddPCR) analyses. (A, C) are control samples with both targeted region (MTAP or CDKN2A) retained. (B, D) are patient formalin fixed paraffin embedded (FFPE) samples showing all positive populations are detectable. In samples having genomic (MTAP or CDKN2A) deletion, the top left population (blue) disappears while the reference population (green) remains. (E) Correlation between CDKN2A ddPCR results and MTAP ddPCR results for MPM and negative control normal pleural tissue samples, with line of linear regression in black (slope =0.8193, y-intercept = 0.2030, R2 = 0.875).
Figure 4
Figure 4
(A, B) Correlation between fluorescence in situ hybridization (FISH) (multiplied by −1, since any one cell containing genomic loss will count as 1) and droplet digital PCR (ddPCR) results (genomic loss will show no detection) for (A) MTAP and (B) CDKN2A, with line of linear regression in black [A: methylthioadenosine phosphorylase (MTAP): slope = 0.003411, y-intercept = 1.034011, R2 = 0.2404; B: CDKN2A: slope = 0.004099, y-intercept = 1.040047, R2 = 0.302].

Similar articles

Cited by

References

    1. Kao SC, Reid G, Lee K, Vardy J, Clarke S, van Zandwijk N. Malignant mesothelioma. Intern Med J (2010) 40(11):742–50. 10.1111/j.1445-5994.2010.02223.x - DOI - PubMed
    1. van Meerbeeck JP, Scherpereel A, Surmont VF, Baas P. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol (2011) 78(2):92–111. 10.1016/j.critrevonc.2010.04.004 - DOI - PubMed
    1. LaDou J, Castleman B, Frank A, Gochfeld M, Greenberg M, Huff J, et al. The case for a global ban on asbestos. Environ Health Perspect (2010) 118(7):897–901. 10.1289/ehp.1002285 - DOI - PMC - PubMed
    1. Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol (2016) 11(8):1246–62. 10.1016/j.jtho.2016.04.028 - DOI - PMC - PubMed
    1. Linton A, Kao S, Vardy J, Clarke S, van Zandwijk N, Klebe S. Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review. Asia Pac J Clin Oncol (2013) 9(3):273–9. 10.1111/ajco.12043 - DOI - PubMed